Welcome to our dedicated page for CYTODYN news (Ticker: CYDY), a resource for investors and traders seeking the latest updates and insights on CYTODYN stock.
CYDY is a clinical-stage biotechnology company focused on developing leronlimab, a humanized IgG4 monoclonal antibody that targets CCR5, a protein on immune system cells. Having invested in clinical trials, CYDY aims to revolutionize treatment across multiple therapeutic areas including HIV, oncology, MASH, and MASLD. Despite facing challenges in FY23, the company took measures to conserve resources, reduce operating expenses, and position itself for near-term and long-term success. CYDY is focused on completing the resolution of the FDA's partial clinical hold and exploring various therapeutic indications for leronlimab to maximize patient and practitioner benefits.
CytoDyn Inc. (OTC.QB: CYDY) announced positive topline results from its CD12 Phase 3 clinical trial focusing on leronlimab for critically ill COVID-19 patients. The study demonstrated significant improvements in mortality rates, showing a 78% reduction with the first dose and 82% with the second. Secondary endpoints were met with statistically significant p-values. Despite not achieving the primary endpoint in the mITT population, CytoDyn aims to submit these findings to regulatory agencies for potential approval in countries like India and the Philippines.
CytoDyn Inc. (OTC.QB: CYDY) announced an investment community webcast scheduled for May 18, 2021, led by CEO Nader Pourhassan and other executives. The presentation will address ongoing communications with the FDA regarding trial design, focusing on the CD12 trial results for the COVID-19 treatment, leronlimab. The trial did not meet primary endpoint criteria; however, secondary endpoints in a critically ill sub-population showed promise. Investors are encouraged to submit questions before and during the webcast.
CytoDyn Inc. (OTC.QB: CYDY) has signed an exclusive agreement with Macleods Pharmaceuticals Ltd. to distribute leronlimab in India, targeting COVID-19 patients. This partnership aims to address the lack of approved treatments for critically ill COVID-19 patients in India. The agreement was finalized swiftly, and both companies are optimistic about leronlimab's potential to save lives. CytoDyn has also completed a pivotal Phase 3 trial for leronlimab in HIV treatment and plans to resubmit its Biologics License Application by Q3 2021.
CytoDyn Inc. (OTC.QB: CYDY) has announced that its drug candidate, leronlimab, will be featured in a one-hour segment on OneNews in the Philippines on May 9, 2021. Leronlimab has been provided to critically ill COVID-19 patients under Compassionate Special Permits from the Philippine FDA. The segment will include key executives from CytoDyn and medical professionals discussing the drug's potential benefits. Leronlimab has successfully met primary endpoints in clinical trials for HIV and is in the process of resubmitting its Biologics License Application.
CytoDyn Inc. (OTC.QB: CYDY) has partnered with Albert Einstein Israelite Hospital in São Paulo, Brazil, to conduct two Phase 3 COVID-19 trials aimed at seeking regulatory approval from ANVISA for leronlimab. These trials will enroll about 1,500 patients across 45 sites, with an interim analysis planned when 120 critically ill patients are enrolled. The Brazilian COVID-19 crisis intensifies with ICU capacity nearing full. CytoDyn believes these trials may facilitate Emergency Use Authorization (EUA) for leronlimab globally. The company plans to update shareholders on trial progress shortly.
CytoDyn Inc. (OTC.QB: CYDY) announced on May 3, 2021, an upcoming webcast scheduled for May 5, 2021, featuring CEO Nader Pourhassan, CMO Scott Kelly, and COO Chris Recknor. The session aims to provide stockholders with updates on the company's priorities, particularly its COVID-19 initiatives and ongoing trials related to COVID-19, NASH, and cancer. Investors can submit questions online for discussion during the one-hour session, which will be accessible through the company's corporate website.
CytoDyn Inc. (OTC.QB: CYDY) has announced plans for a pre-Breakthrough Therapy designation meeting to expedite preparations for a Phase 3 clinical trial involving leronlimab for 22 solid tumor cancer indications. Encouraging results from preliminary trials suggest potential for a reduced trial size. The company is optimistic about leronlimab's ability to control cancer metastasis and its role in immunotherapy. Additionally, CytoDyn is preparing to resubmit its Biologics License Application (BLA) for HIV treatment, following previous setbacks.
CytoDyn Inc. (OTC.QB: CYDY) announced progress on its HIV treatment, leronlimab, following positive results from three ongoing clinical trials. Approximately 120 patients remain in treatment extensions, with no significant safety issues reported over 4-7 years in 66 open-label patients. The company is on track to submit a Biologics License Application (BLA) for HIV therapy by July 2021, aiming to expedite additional indications, including cancer and COVID-19. Leronlimab has shown promise in controlling HIV viral load, indicating a potential breakthrough in treatment options.
CytoDyn Inc. (OTC.QB: CYDY) announced that Scott Kelly, M.D., will present on leronlimab at the Triple Negative Breast Cancer Drug Development Digital Summit 2021 on April 28. This exclusive event aims to discuss leronlimab's potential in treating triple-negative breast cancer (TNBC), with encouraging early indications noted. The FDA has granted leronlimab Fast Track designation for HIV and metastatic cancer indications. CytoDyn is conducting multiple clinical trials to explore its efficacy across various diseases.
CytoDyn Inc. (OTC.QB: CYDY) announced it secured $57 million in financing, with a recent $25 million convertible debt offering. The note has a two-year maturity at 10% interest, convertible at $10 per share. CytoDyn continues to focus on key therapeutic areas, including COVID-19 and HIV, with significant progress in its clinical trials. Key highlights include the expectation of HIV BLA resubmission by Q3 2021 and ongoing trials for long-haulers and NASH. The company has raised nearly $500 million, reflecting strong market confidence.
FAQ
What is the current stock price of CYTODYN (CYDY)?
What is the market cap of CYTODYN (CYDY)?
What operational and financial adjustments did the Company make in fiscal year 2023?
What is the status of the clinical hold?
What is the short-term development plan for leronlimab following the resolution of the clinical hold?
What is the current status of the longer-acting therapeutic project?
What is the current status of the CEO search?
How does the Company make decisions regarding executive compensation?
What is the current status of the Amarex litigation effort?
What is the status of the new communication strategy?
What clinical trials is the Company currently working on?